tag:blogger.com,1999:blog-36634196.post8720928599744288199..comments2023-10-09T11:33:37.853-05:00Comments on The IN VIVO Blog: Financings of the Fortnight Is Innocent Until Proven GuiltyChris Morrisonhttp://www.blogger.com/profile/04075266444951558159noreply@blogger.comBlogger1125tag:blogger.com,1999:blog-36634196.post-37485613524327406202011-03-05T23:00:29.115-05:002011-03-05T23:00:29.115-05:00Very insightful reporting, thanks. Cephalon is lea...Very insightful reporting, thanks. Cephalon is leading the charge in the new wave of "biological drugs" which are harder for competitors to reverse engineer and copy. PII results just published in Nature showed that Cephalon's "off-the-shelf" stem cell drug Revascor reduced MACE (Major Adverse Cardiac Events: chest pain, heart attack, death, etc) by an unprecedented 84%, virtually curing heart disease with a single injection. If you can afford it, the drug has been approved for treatment in Australia. Even though they just beat earnings, raised EPS targets, are net positive cash and have the highest FCF/share of any biotech, Cephalon is approaching a 52-week low and has the highest short interest of any stock in the S&P 500. Go figure. http://bit.ly/i1pYmrAnonymousnoreply@blogger.com